| Serial Number | 98247807 |
| Word Mark | AHMEMZO |
| Filing Date | Tuesday, October 31, 2023 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, May 13, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 13, 2025 |
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T-Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical and clinical use; Pharmaceutical preparations for human use for the treatment and prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment and prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic agents, preparations and substances for medical purposes for human use; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer for human use; pharmaceutical preparations for human use in the nature of radio-isotope markers for therapeutic and diagnostic use. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 9, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Event Date | Event Description |
| Thursday, November 9, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, June 14, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, November 3, 2023 | NEW APPLICATION ENTERED |
| Monday, June 10, 2024 | ASSIGNED TO EXAMINER |
| Friday, June 14, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, June 14, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, September 11, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, September 11, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, September 11, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 9, 2024 | FINAL REFUSAL WRITTEN |
| Wednesday, October 9, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, October 9, 2024 | FINAL REFUSAL E-MAILED |
| Thursday, January 9, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, January 9, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 9, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Thursday, February 13, 2025 | ACTION CONTINUING A FINAL - COMPLETED |
| Thursday, February 13, 2025 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED |
| Thursday, February 13, 2025 | CONTINUATION OF FINAL REFUSAL E-MAILED |
| Monday, March 10, 2025 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Monday, March 10, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, April 10, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 7, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 13, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 13, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Monday, March 10, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |